Roche's innovative sequencing by expansion (SBX) technology represents a leap forward in next-generation sequencing (NGS), ...

Scientists have identified novel genetic interactions that may contribute to congenital heart disease (CHD), a common birth defect.

Scientists at the Icahn School of Medicine at Mount Sinai and collaborators have identified novel genetic interactions that may contribute to congenital heart disease (CHD), a common birth defect.

Roche's innovative sequencing by expansion (SBX) technology represents a leap forward in next-generation sequencing (NGS), which is playing a vital role in decoding complex diseases like cancer, immun ...

GeneDx excels in comprehensive genome and exome testing using a vast genetic database linking 400+ diseases. See why I think ...

Q4 2024 Earnings Call Transcript February 18, 2025 GeneDx Holdings Corp. beats earnings expectations. Reported EPS is $0.62, ...

GeneDx Holdings Corp (WGS) reports robust revenue growth and unveils new products, despite facing reimbursement challenges.

GeneDx stock catapulted Tuesday after the top-notch biotech smashed fourth-quarter expectations and issued upbeat guidance.

Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease characterized by the progressive degeneration ...

President and CEO Katherine Stueland stated that GeneDx achieved significant milestones in 2024, including surpassing $95 million in Q4 revenue and expanding gross margins to 70%. She highlighted the ...

GeneDx Holdings Corp. (Nasdaq: WGS) today reported its financial results for the fourth quarter and full year of 2024.